A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)

Trial Profile

A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Urogenital cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate 274
  • Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
  • Most Recent Events

    • 12 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
    • 29 Mar 2017 Planned End Date changed from 1 Oct 2020 to 1 May 2020.
    • 29 Mar 2017 Planned primary completion date changed from 1 Oct 2020 to 1 Apr 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top